Stroke Central Atlantic Network for Research (SCANR)

中风中央大西洋研究网络 (Scanr)

• 批准号: 10445096
• 负责人: BARBARA S BREGMAN
• 金额: $ 30.04万
• 依托单位: MEDSTAR HEALTH RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-15 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10445096
• 关键词: Acute; Adult; African American; Area; Arteries; Baltimore; Biological Markers; Black race; Blood Vessels; Brain; Cerebral Amyloid Angiopathy; Cerebrum; Cervical; Child; Childhood; Childhood stroke; Clinical; Clinical Research; Dissection; Doctor of Philosophy; Enrollment; Extramural Activities; Fellowship Program; Funding; Genetic; Health Disparities Research; Historically Black Colleges and Universities; Hospitals; Image; Individual; Institution; Intervention; Leadership; Link; Magnetic Resonance Imaging; Maryland; Medical center; Mentored Clinical Scientist Development Program; Mentors; Mentorship; Mid-Atlantic Region; Multimodal Imaging; National Institute of Neurological Disorders and Stroke; Neurologist; Neurology; Participant; Patient Recruitments; Patients; Persons; Phase; Phenotype; Play; Positioning Attribute; Prevention; Prevention trial; Process; Registries; Rehabilitation therapy; Reporting; Research; Research Institute; Research Personnel; Research Training; Residencies; Resources; Robotics; Role; Scientist; Secondary Prevention; Site; Stroke; Stroke Belt; StrokeNet trials; Training; Translating; Translational Research; Universities; Venous Thrombosis; Virginia; Washington; acute stroke; base; career; career development; cerebrovascular; experience; innovation; microbiome research; multidisciplinary; multimodality; multiple omics; neurological rehabilitation; news; novel; participant retention; patient population; programs; recruit; rehabilitation research; research and development; rural setting; screening; stroke incidence; stroke patient; stroke rehabilitation; stroke trials; treatment trial; urban setting

SCANR, the Stroke Central Atlantic Network for Research is based in the Mid-Atlantic region and headquartered in Washington, DC, and Charlottesville, VA. SCANR is located on the edge of the Stroke Belt, and both DC and Baltimore have high stroke incidence. SCANR includes four Carnegie Research 1 universities (Georgetown and George Washington Universities; the Universities of Virginia and Maryland), two CTSAs, a translational research institute (THRIV), a US News & World Report National Honor Roll Hospital (Children's National Medical Center), the largest hospital in DC (MedStar Washington Hospital Center), two Historically Black Universities (Howard University and University of DC) and the NINDS Intramural Stroke Program. SCANR sites evaluated over 4100 acute strokes in 2016, >50% were Black/African American. Our NINDS-funded trial recruitment is excellent, screening all eligible patients for and enrolling in StrokeNet trials: DEFUSE 3, MISTIE 3, HiDef, Rhapsody, SHINE, POINT, and MR WITNESS, along with additional NINDS-funded trials. SCANR also includes the National Coordinating Center for SHINE (UVa, Johnston-PI), and the CREST-2 registry and imaging core (UMB, Lal). SCANR 2.0 continues to have all of the excellent qualities that made SCANR 1.0 a strong contender for StrokeNet selection: pediatric stroke and stroke rehabilitation, patient populations and innovative recruitment practices for health disparities research, and the link to the NINDS Intramural Stroke Program. These strengths will stand out with the pediatric, rehab, and pediatric rehab trials in the StrokeNet pipeline. SCANR 2.0 includes UVa as a high-performing site for acute treatment and prevention trials. UVa also provides expertise in biomarkers, genetics, and prehospital research. The addition of UVa and UMB made SCANR a truly regional Coordinating Center. SCANR 2.0 research expertise includes multimodal imaging, microbiomics, multi-omics, Neurorehabilitation trials, brain stimulation, and robotics. We are well positioned to translate early phase NINDS intramural studies into the extramural setting. We have a track record of recruiting substantial numbers of specific cerebrovascular phenotypes (cervical artery dissection, cerebral venous thrombosis, cerebral amyloid angiopathy, etc.). Our consortium of academic rehab hospitals is outstanding. We currently have four trial proposals submitted to StrokeNet in varying stages of the process. Our existing Participant Recruitment and Retention Core (PRRO Core) has played a leadership role in the StrokeNet network. SCANR investigators serve on national StrokeNet steering committees and cores. Our StrokeNet fellows have diverse clinical backgrounds (2 vascular neurologists, 1 PT PhD, 1 OT) and subsequently, they successfully compete for external funding (TL-2, KL-2, AHA). They have opportunities for outstanding research training and mentorship across our Mid-Atlantic institutions, preparing them for productive research careers. SCANR investigators recently successfully established a novel national K12 program for rehabilitation research. We currently have 5 relevant fellowship programs and three adult neurology residencies at the SCANR 2.0 sites. This training joins strong multidisciplinary clinical and research expertise in stroke with much experience in research and career development of clinician scientists.

SCANR，中大西洋中风研究网络，总部设在大西洋中部地区，总部位于 华盛顿特区和弗吉尼亚州夏洛茨维尔。 SCANR 位于中风带的边缘，华盛顿特区和巴尔的摩 中风发病率很高。 SCANR 包括四所卡内基研究 1 大学（乔治城大学和乔治华盛顿大学、弗吉尼亚大学和马里兰大学）、两所 CTSA、一个转化研究所 (THRIV)、一家美国新闻与世界报道国家荣誉医院（儿童国家医疗中心）、华盛顿特区最大的医院（MedStar 华盛顿医院中心）、两所历史黑人大学（霍华德大学和华盛顿大学）以及 NINDS 校内中风计划。 SCNR 网站在 2016 年评估了超过 4100 例急性中风，其中超过 50% 是黑人/非裔美国人。我们的 NINDS 资助的试验 招募工作非常出色，筛选了所有符合条件的患者并参加了 StrokeNet 试验：DEFUSE 3、MISTIE 3、HiDef、 Rhapsody、SHINE、POINT 和 MR WITNESS，以及 NINDS 资助的其他试验。扫描还包括 SHINE 国家协调中心（UVa、Johnston-PI）以及 CREST-2 注册和成像核心（UMB、Lal）。 SCANR 2.0 继续拥有使 SCANR 1.0 成为 StrokeNet 强有力竞争者的所有优秀品质 选择：儿科中风和中风康复、患者群体和创新的健康招募实践 差异研究，以及与 NINDS 壁内中风计划的链接。这些优势将脱颖而出 StrokeNet 管道中的儿科、康复和儿科康复试验。 SCNR 2.0 包括 UVa 作为高性能站点 用于急性治疗和预防试验。弗吉尼亚大学还提供生物标志物、遗传学和院前研究方面的专业知识。 UVa 和 UMB 的加入使 SCANR 成为真正的区域协调中心。 SCNR 2.0 研究专业知识包括多模态成像、微生物组学、多组学、神经康复试验、脑刺激和机器人技术。我们处于有利地位，可以将早期 NINDS 校内研究转化为校外环境。我们有招募大量特定脑血管表型（颈动脉 夹层、脑静脉血栓、脑淀粉样血管病等）。我们的学术康复医院联盟非常出色。目前，我们已在流程的不同阶段向 StrokeNet 提交了四项试验提案。我们现有的参与者招募和保留核心（PRRO 核心）在 StrokeNet 网络中发挥了领导作用。 SCNR 调查员在国家 StrokeNet 指导委员会和核心部门任职。我们的 StrokeNet 研究员拥有不同的临床背景（2 名血管神经科医生、1 名 PT 博士、1 名 OT），随后，他们成功竞争外部资金（TL-2、KL-2、AHA）。他们有机会在我们的中大西洋机构中接受杰出的研究培训和指导，为他们从事富有成效的研究职业做好准备。 SCNR 研究人员最近成功建立了一项新颖的国家 K12 康复研究计划。目前，我们在 SCNR 2.0 站点有 5 个相关的研究金项目和 3 个成人神经病学住院医师项目。该培训结合了中风方面强大的多学科临床和研究专业知识以及临床科学家在研究和职业发展方面的丰富经验。